1. Proceedings from the National Cancer Institute’s Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part III. Prevention and Treatment of Relapse after Allogeneic Transplantation 
Marcos de Lima, David L. Porter, Minoo Battiwalla, Michael R. Bishop, Sergio A. Giralt, Nancy M. Hardy, Nicolaus Kröger, Alan S. Wayne, Christoph Schmid 
Biology of Blood and Marrow Transplantation 
Volume 20, Issue 1, Pages 4-13 (January 2014)
DOI: /j.bbmt
Copyright © Terms and Conditions

2. Figure 1
Donor–cell consolidation of remission for AML relapse after AlloSCT. Analysis of European Bone Marrow Transplantation Registry data from 38 patients in CR after first-line cytoreductive therapy for relapsed AML after AlloSCT demonstrated improved OS with use of donor cells for consolidation: 55% ± 11% vs. 20% ± 10% (P = .038). DLI and second AlloSCT were considered as time-dependent variables.
Adapted from [30].
Biology of Blood and Marrow Transplantation  , 4-13DOI: ( /j.bbmt )
Copyright © Terms and Conditions

3. Figure 2
Theoretical relative therapeutic potential of cellular therapies for relapse. The shaded quadrant represents the zone of optimal specificity with respect to tumor versus off-target cytotoxic tissue damage, which maximizes antitumor potency and minimizes cell-mediated morbidity. Conventional DLI and second AlloSCT (depicted in red) are the currently available cell-based treatments for relapse, against which novel therapies (blue) will be judged. TAA, tumor-associated antigen; MiAg, minor histocompatibility antigen.
Biology of Blood and Marrow Transplantation  , 4-13DOI: ( /j.bbmt )
Copyright © Terms and Conditions